Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    02076399 | thrombocytopenia
Previous Study | Return to List | Next Study

A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (FIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02076399
Recruitment Status : Completed
First Posted : March 3, 2014
Results First Posted : January 11, 2019
Last Update Posted : February 12, 2019
Sponsor:
Information provided by (Responsible Party):
Rigel Pharmaceuticals

Brief Summary:
The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of persistent/chronic Immune Thrombocytopenic Purpura (ITP).

Condition or disease Intervention/treatment Phase
Immune Thrombocytopenic Purpura Drug: Fostamatinib disodium Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 76 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
Actual Study Start Date : July 14, 2014
Actual Primary Completion Date : April 21, 2016
Actual Study Completion Date : April 21, 2016


Arm Intervention/treatment
Experimental: Fostamatinib Disodium
Subjects begin with Fostamatinib Disodium tablet 100 mg PO bid and increase to 150 mg big after week 4 based on platelet count and tolerability.
Drug: Fostamatinib disodium
Fostamatinib (100 mg PO bid or 150 mg PO bid)
Other Names:
  • R935788
  • R788
  • Fostamatinib

Placebo
Placebo tablet PO bid (morning and evening) over the course of 24 weeks
Drug: Placebo
Placebo tablet PO bid (morning and evening) over the course of 24 weeks




Primary Outcome Measures :
  1. Number of Participants With Stable Platelet Response (Count of ≥50,000/µL on at Least 4 of the Last 6 Scheduled Visits Between Weeks 14 and 24) [ Time Frame: From Week 14 to Week 24 ]
    A stable platelet response by Week 24 defined as a platelet count of at least 50,000/μL on at least 4 of the last 6 scheduled visits between Weeks 14 and 24


Secondary Outcome Measures :
  1. Number of Participants With Platelet Count ≥ 50,000/µL at Week 12 [ Time Frame: Week 12 ]
    Platelet Count ≥ 50,000/µL at Week 12

  2. Number of Participants With Platelet Count ≥ 50,000/µL at Week 24 [ Time Frame: Week 24 ]
    Platelet Count ≥ 50,000/µL at Week 24

  3. Platelet Count ≥ 30,000/μL and ≥ 20,000/μL Above Baseline in Subjects With Baseline Platelet Count of <15,000/μL at Week 12. [ Time Frame: Baseline to Week 12 ]
    Number of subjects with baseline platelet count <15,000/μL who showed platelet count increase to ≥30,000/μL and ≥20,000/μL from baseline count at Week 12.

  4. Platelet Count ≥ 30,000/μL and ≥ 20,000/μL Above Baseline in Subjects With Baseline Platelet Count of <15,000/μL at Week 24. [ Time Frame: Baseline to Week 24 ]
    Number of subjects with baseline platelet count <15,000/μL who showed platelet count increase to ≥30,000/μL and ≥20,000/μL from baseline count at Week 24.

  5. Mean of the ITP Bleeding Score (IBLS) [ Time Frame: Assessed over the 24-week study period ]

    The ITP Bleeding Scale (IBLS) is an immune thrombocytopenic purpura (ITP)-specific bleeding score used to analyze the correlation of clinical and laboratory platelet variables with bleeding. The IBLS comprises of 11 grades from 0 (none) to 2 (marked bleeding) by history over the previous week or by exam; 2 being worse. These 11 grades include: skin by physical exam, oral by physical exam, skin by history, oral by history, epistaxis, gastrointestinal, urinary, gynecological, pulmonary, intracranial hemorrhage, and subconjunctival hemorrhage. After each grade is scored, the mean value for all 11 grades is calculated (lowest score being 0 and highest score being 2) for each subject visit. LOCF method was used to impute any missing data.

    The mean of the IBLS scores across visits during the 24-week treatment period was summarized by treatment group using descriptive statistics. A 2-sided, 2-sample t-test was used to test for a difference in means between treatments for this endpoint.


  6. Mean of World Health Organization (WHO) Bleeding Scale [ Time Frame: Assessed over the 24-week study period ]

    The World Health Organization (WHO) bleeding scale is a standardized grading scale created to measure the severity of bleeding. The scale is a clinical investigator-assessed five-point scale with a score range starting at the lowest 0=No bleeding, 1 = Petechiae, 2=Mild blood loss, 3=Gross blood loss, to the worse 4=Debilitating blood loss. The WHO bleeding scale is scored by history over the previous-week or by exam. After each grade is scored, the mean value is calculated (lowest score being 0 [no bleeding] to the highest score being 4 [debilitating blood loss]) for each visit. LOCF method was used to impute any missing data.

    The mean of the WHO bleeding scale across visits during the 24-week treatment period was summarized by treatment group using descriptive statistics. A 2-sided, 2-sample t-test was used to test for a difference in means between treatments for this endpoint.




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of persistent/chronic ITP for at least 3 months.
  • Average platelet count < 30,000/µL (and none > 35,000 unless as a result of rescue therapy) from at least 3 qualifying counts

Exclusion Criteria:

  • Clinical diagnosis of autoimmune hemolytic anemia
  • Uncontrolled or poorly controlled hypertension
  • History of coagulopathy including prothrombotic conditions

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02076399


  Hide Study Locations
Locations
Layout table for location information
United States, Arizona
Arizona Oncology Associates
Tucson, Arizona, United States, 85710
United States, California
University of Southern California
Los Angeles, California, United States, 90089
United States, Florida
Lakeland Regional Cancer Center
Lakeland, Florida, United States, 33805-1965
United States, Illinois
Bleeding & Clotting Disorders Institute
Peoria, Illinois, United States, 61614
United States, Indiana
Horizon Oncology Research, Inc
Lafayette, Indiana, United States, 47905
United States, Maryland
Center for Cancer and Blood Disorders
Bethesda, Maryland, United States, 20817
United States, New York
Weill Cornell Medical College/New York Presbyterian Hospital
New York, New York, United States, 10065
United States, North Carolina
Pitt County Memorial Hospital
Greenville, North Carolina, United States, 27858
Bill Hefner VA Medical Center
Salisbury, North Carolina, United States, 28144
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Signal Point Clinical Research Center LLC
Middletown, Ohio, United States, 45042
United States, Utah
University of Utah Health Sciences Center
Salt Lake City, Utah, United States, 84132
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States, 22908
Australia, New South Wales
Concord Repatriation General Hospital
Concord, New South Wales, Australia, 2139
St George Hospital
Kogarah, New South Wales, Australia, 2217
Liverpool Hospital
Liverpool, New South Wales, Australia, 2170
Prince of Wales Hospital
Randwick, New South Wales, Australia, 2031
Westmead Hospital
Westmead, New South Wales, Australia, 2145
Australia, Tasmania
Launceston General Hospital
Launceston, Tasmania, Australia, 7250
Australia, Victoria
Frankston Hospital
Frankston, Victoria, Australia, 3199
Dept of Haematology, The Alfred Hospital and Monash Medical Centre
Melbourne, Victoria, Australia, 3004
Australia, Western Australia
Perth Blood Institute
Nedlands, Western Australia, Australia, 6009
Canada, Ontario
Hamilton Health Sciences Corporation
Hamilton, Ontario, Canada, L8N 3Z5
Ottawa Hospital Research Institute
Ottawa, Ontario, Canada, K1 H8L6
St. Michael's Hospital
Toronto, Ontario, Canada, M5B1W8
Denmark
Herlev Hospital University of Copenhagen, Department of Hematology L124
Herlev, DK, Denmark, 2730
Dept. of Haematology, Odense University Hospital
Odense C, DK, Denmark, DK-5000
Hematological department, Roskilde Hospital
Roskilde, DK, Denmark, 4000
Aarhus University Hospital
Aalborg, Denmark, 9000
Hungary
Semmelweis University 1st
Budapest, Hungary, H-1083
University of Debrecen
Debrecen, Hungary, H-1083
Pecs University
Pecs, Hungary, H-7624
Italy
Ematologia - Padigilione 8, Policinico S. Orsola Malpighi, Azienda Ospedaliero Universitaria di Bologna
Bologna, Italy, 40138
Ospedale San Raffaele S.r.l. Dipartimento di Oncoematologia
Milano, Italy, 20132
Universitã Federico II di Napoli
Napoli, Italy, 80131
OspedaleCivile-ClinicaEmatologica/PUGD
Udine, Italy, 33100
ULSS 6 Vicenza-Ospedale San Bortolo di Vicenza
Vicenza, Italy
Netherlands
HAGA ziekenhuis
Haag, NL, Netherlands, 2545 CH
United Kingdom
Kent & Canterbury Hospital
Kent, Canterbury, United Kingdom, CT1 3NG
Colchester General Hospital
Colchester, Essex, United Kingdom, CO4 5JL
Royal Liverpool University Hospital
Liverpool, UK, United Kingdom, L78XP
St. James's Hospital
Leeds, United Kingdom, LS9 7TF
Leicester Royal Infirmary
Leicester, United Kingdom, LE1 5WW
Royal London Hospital
London, United Kingdom, E1 2ES
Hammersmith Hospital, Catherine Lewis Centre
London, United Kingdom, W12 0HS
University College Hospital
London, United Kingdom, WC1E 6HX
Manchester Royal Infirmary
Manchester, United Kingdom, M139WL
Royal Victoria Infirmary
Newcastle-upon-Tyne, United Kingdom, NE1 4LP
James Paget University Hospital
Norfolk, United Kingdom, NR31 6LA
Oxford University Hospital
Oxford, United Kingdom, OX3 9BQ
University Hospital of North Staffordshire
Stoke-on-Trent, United Kingdom, ST4 6QG
Sandwell General Hospital
West Bromwich, United Kingdom, B71 4HJ
Sponsors and Collaborators
Rigel Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Rigel Pharmaceuticals, Inc. Rigel Pharmaceuticals, Inc.

Layout table for additonal information
Responsible Party: Rigel Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02076399     History of Changes
Other Study ID Numbers: C-935788-047
2013-005452-15 ( EudraCT Number )
First Posted: March 3, 2014    Key Record Dates
Results First Posted: January 11, 2019
Last Update Posted: February 12, 2019
Last Verified: October 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Rigel Pharmaceuticals:
Persistent Immune Thrombocytopenic Purpura
Chronic Immune Thrombocytopenic Purpura
Additional relevant MeSH terms:
Layout table for MeSH terms
Thrombocytopenia
Purpura
Purpura, Thrombocytopenic
Purpura, Thrombocytopenic, Idiopathic
Blood Coagulation Disorders
Hematologic Diseases
Hemorrhage
Pathologic Processes
Skin Manifestations
Signs and Symptoms
Thrombotic Microangiopathies
Blood Platelet Disorders
Immune System Diseases
Hemorrhagic Disorders
Autoimmune Diseases